Guidance and language shifted from reiterating 2026 net revenue guidance of $900 million to $920 million to raising it to $930 million to $945 million, attributed to Q1 prescribing breadth/depth.
Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results